Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE)

Background: Multiple sclerosis (MS) is an autoimmune disease causing multifocal demyelination and axonal injuries in the central nervous system (CNS). Toll-interleukin-1 receptor (TIR)-domain containing adaptor protein-inducing interferon beta (TRIF) is an important adaptor protein for Toll-like receptors (TLRs) and can modulate the immune response via regulating cytokine secretion. This study investigated the potential function of TRIF in MS mice via small interference RNA (siRNA). Material/Methods: Isolated mouse lymphocytes were processed using TRIF siRNA, followed by RT-PCR assay to quantify TRIF expression level. An experimental allergic encephalomyelitis (EAE) model was prepared in C57BL/6 mice immunized with MOG 35-55. TRIF siRNA or controlled siRNA were intravenously applied to evaluate the neurological function of animals. Serum levels of IFN-gamma and IL-2 were observed. Results: Specific siRNA effectively decreased the TRIF expression in mouse dendritic cells and this siRNA improved the EAE severity and neurological scores. Further assays showed that both IFN-gamma and IL-2 levels in the siRNA treatment group were significantly lower than in controls. Conclusions: The expression of TRIF can be down-regulated by siRNA, thereby alleviating the severity of EAE via its inhibition of interleukin and cytokine release. This may provide new insights for future treatment of MS.